Search Results

491 Results for "verve therapeutics.rss".

Sort By

Gene editing

Verve’s Base Editor ‘Numerically Beats’ Other Cholesterol-Lowering Drugs

In a Phase Ib trial, VERVE-102 showed it could lower bad cholesterol across doses, setting up an opt-in decision for Eli Lilly and a showdown with Novartis.

April 14, 2025
·
2 min read
·
Dan Samorodnitsky
Press Releases

Lilly and Verve announce expiration of Verve tender offer

July 25, 2025
·
5 min read
Gene editing

‘Safer’ CRISPR: Base Editing Breaks Through in the Clinic as Beam, Verve Advance

Beam Therapeutics and Verve Therapeutics have each built their lead candidates on a technique billed as a safer alternative to conventional CRISPR. Clinical results have so far been promising.

May 5, 2025
·
9 min read
·
Shawna Williams
Mergers & acquisitions

Lilly-Verve Proxy Filing Reveals Tumult After Departure of FDA’s Marks

Jefferies analysts called the proxy filing, which is a standard disclosure after a merger agreement, “much more intriguing than normal” given the regulatory turmoil it revealed.

June 26, 2025
·
4 min read
·
Annalee Armstrong
Press Releases

Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk

July 25, 2025
·
3 min read
Press Releases

Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk

June 17, 2025
·
12 min read
Mergers & acquisitions

Lilly Validates Gene Editing Space With $1.3B Verve Buy, But Analysts Are Skeptical

The pending deal was rumored overnight after a report from the Financial Times, spurring analysts to speculate that if true, the entire gene editing space would see a boost at the markets.

June 17, 2025
·
3 min read
·
Annalee Armstrong
Metabolic disorders

Lilly Makes $1.2B RNAi Pact With SangeneBio, Targets Metabolic Diseases

Eli Lilly has been on a dealmaking spree this year, with a few deals worth $1 billion or more. Aside from SangeneBio, these include SiteOne, Verve and Scorpion.

November 10, 2025
·
2 min read
·
Tristan Manalac
Gene therapy

Vertex Severs Liver Gene Therapies Partnership With Verve

The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies together.

February 27, 2025
·
2 min read
·
Dan Samorodnitsky
Drug Development

Verve’s Gene Editor Cuts Cholesterol in First-in-Human HeFH Trial

When given at potentially therapeutic doses, Verve’s base editor led to strong reductions in LDL cholesterol and PCSK9 levels in patients with heterozygous familial hypercholesterolemia.

November 13, 2023
·
2 min read
·
Tristan Manalac